(MedPage Today) — Dual therapy with the investigational oral tyrosine kinase inhibitor (TKI) apatinib plus anti-PD-1 checkpoint blockade was safe and yielded modest activity in soft-tissue sarcoma, a phase I open-label trial showed.
Among 30…
Read More